PERSPECTA

News from every angle

← Back to headlines

Climb Bio Receives FDA Fast Track Designation and BTIG Buy Rating

Climb Bio (CLYM) has been granted FDA Fast Track designation, and BTIG has issued a "Buy" rating for the small-cap stock. This news has sparked discussions about the company's investment potential.

20 Apr, 14:48 — 20 Apr, 14:48
PostShare

Sources

Showing 1 of 1 sources
YahooMostly Factual56d ago

FDA Fast Track and a BTIG Buy; Is Climb Bio (CLYM) a Must-Buy Small Cap Stock?

Read full article →

Related Stories

Extreme Training: What Heat Training Does to the Body

just now

How Does One Brain Speak Two Languages?

18m ago

Foods Rich in Antioxidants May Aid Skin Protection from Sun

20m ago

Study Explores Link Between Alcohol Consumption and Junk Food Cravings

33m ago